Hearing traders are eyeing Amylin Pharmaceuticals (Nasdaq: AMLN) ahead of an expected FDA ruling on Type 2 diabetes drug, Exenatide ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE